[1]王登,王娣,曹青,等.基于ACE2受体探讨玉屏风散预防新型冠状病毒肺炎的网络药理学机制[J].西部中医药,2023,36(02):18-23.[doi:10.12174/j.issn.2096-9600.2023.02.04]
　WANG Deng,WANG Di,CAO Qing,et al.Network Pharmacology Mechanism of Yupingfeng Powder for the Prevention of COVID-19 Based on ACE2 Receptor[J].Western Journal of Traditional Chinese Medicine,2023,36(02):18-23.[doi:10.12174/j.issn.2096-9600.2023.02.04]
点击复制

基于ACE2受体探讨玉屏风散预防新型冠状病毒肺炎的网络药理学机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年02期
页码:
18-23
栏目:
出版日期:
2023-02-15

文章信息/Info

Title:
Network Pharmacology Mechanism of Yupingfeng Powder for the Prevention of COVID-19 Based on ACE2 Receptor
作者:
王登1, 王娣2, 曹青1, 闫抗抗1
1.西北大学附属医院/西安市第三医院，陕西 西安 710018
2.陕西省中医药研究院，陕西 西安 710016
Author(s):
WANG Deng1, WANG Di2, CAO Qing1, YAN Kangkang1
1.Xi'an No.3 Hospital/the Affiliated Hospital of Northwest University, Xi'an 710018, China
2.Shaanxi Academy of Traditional Chinese Medicine, Xi'an 710016, China
关键词:
新型冠状病毒肺炎; 玉屏风散; 血管紧张素转化酶2; 网络药理学
Keywords:
COVID-19; powder; ACE2 receptor; network pharmacology
分类号:
R563.1
DOI:
10.12174/j.issn.2096-9600.2023.02.04
文献标志码:
A
摘要:
目的运用网络药理学方法研究玉屏风散介导血管紧张素转化酶2（angiotensin conver-ting enzyme 2，ACE2）受体预防新型冠状病毒肺炎（Corona Virus Disease 2019，COVID-19）的多成分、多靶点、多通路作用机制，为其基础研究及临床应用提供依据。 方法通过数据库检索并筛选玉屏风散的活性成分和对应靶点，并寻求与ACE2受体基因相关的交集靶点；通过Cytoscape软件构建药物-成分-靶点-疾病网络图，利用STRING数据库进行蛋白相互作用分析，寻求关键靶点；采用DAVID数据库进行GO、KEGG富集分析，寻求玉屏风散介导ACE2受体预防COVID-19的潜在作用通路。 结果玉屏风散中筛选得到44个活性成分，涉及CASP3、EGFR、PRKCB、ESR1、EGF等56个ACE2相关靶点。GO和KEGG富集分析显示，玉屏风散主要涉及缺乏配体时的体外凋亡信号通路、凋亡过程负调控、凋亡线粒体的变化等105个显著相关生物过程。玉屏风散主要通过癌症通路、HIF-1信号通路、PI3K-Akt信号通路等通路介导ACE2受体来发挥预防COVID-19的作用。 结论玉屏风散可能通过多成分、多靶点、多途径调控ACE2受体而发挥预防COVID-19的作用，为进一步开展作用机制研究提供了理论基础。
Abstract:
ObjectiveTo study the mechanism of Yupingfeng powder-mediated ACE2 receptor in the prevention of COVID-19 via multi-ingredients, multi-targets and multi-pathways through using network pharmacology method, so as to provide the reference for its basic study and clinical application. MethodsThe active ingredients and the corresponding targets of Yupingfeng powder were searched and screened from the database, the intersections of the targets related to ACE2 receptor gene were surveyed; network chart of medicine-ingredients-targets-disease was constructed by Cytoscape software, protein interaction analysis was conducted by utilizing STRING database, to find out the key targets; GO and KEGG enrichment analysis were performed by using DAVID database, to survey the potential pathway of Yupingfeng powder-mediated ACE2 receptor in the prevention of COVID-19. ResultsA total of 44 active ingredients were yielded from Yupingfeng powder, involving 56 ACE2 related targets such as CASP3, EGFR, PRKCB, ESR1, EGF and others. GO and KEGG enrichment analysis showed that Yupingfeng powder mainly referred to 105 significantly associated biological processes including in-vitro apoptosis signaling pathway, negative regulation of apoptosis process, and the changes of apoptotic mitochondria in the absence of ligands. Yupingfeng powder could prevent COVID-19 possibly through cancer pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway mediating ACE2 receptor. ConclusionYupingfeng powder could prevent COVID-19 possibly through regulating ACE2 receptor via multi-ingredients, multi-targets and multi-pathways, and it could provide theoretical foundation for further study on the mechanism.

相似文献/References:

[1]李永鸿.玉屏风散加味治疗小儿反复呼吸道感染43例[J].西部中医药,2013,26(06):60.
　LI Yonghong.Modified YuPingFeng San in Treating 43 Cases of Recurrent Respiratory Tract Infection in Children[J].Western Journal of Traditional Chinese Medicine,2013,26(02):60.
[2]李雪嫣,张李峰,桂曼曼,等.复方玉屏风散对小鼠细胞免疫力的增强作用研究[J].西部中医药,2013,26(08):11.
　LI Xueyan,ZHANG Lifeng,GUI Manman,et al.Study on Compound YuPingFengSan Oral Liquid Improving Cellular Immunity of Mice[J].Western Journal of Traditional Chinese Medicine,2013,26(02):11.
[3]刘麒.玉屏风散合桂枝汤治疗肺卫不固型自汗43例[J].西部中医药,2015,28(06):98.[doi:2015/6/16 0:00:00]
[4]胡静雪,师建国.艾灸联合玉屏风散治疗小儿脾胃虚弱型泄泻38例[J].西部中医药,2017,30(02):84.
　Moxa with YuPingFeng San in Treating 8 Cases of Infantile Diarrhea of Weakness of the Spleen and Stomach.Moxa with YuPingFeng San in Treating 38 Cases of Infantile Diarrhea of Weakness of the Spleen and Stomach[J].Western Journal of Traditional Chinese Medicine,2017,30(02):84.
[5]李赟,王彩弟,王建云,等.简约远程中医诊疗在新型冠状病毒肺炎隔离病区中的应用[J].西部中医药,2020,33(S1):1.
　LI Yun,WANG Caidi,WANG Jianyun,et al.The Application of Simple Remote TCM Diagnosis and Treatment to COVID-19 Quarantined Inpatient Area[J].Western Journal of Traditional Chinese Medicine,2020,33(02):1.
[6]宋忠阳,雍文兴,张利英,等.新型冠状病毒肺炎的中医临床特征与辨证论治——甘肃经验*[J].西部中医药,2020,33(S1):3.
　SONG Zhongyang,YONG Wenxing,ZHANG Liying,et al.The Experience of TCM Clinical Characteristics, Syndrome Differentiation and Treatment for COVID-19 in Gansu Province[J].Western Journal of Traditional Chinese Medicine,2020,33(02):3.
[7]杜洪霖,马战平△.西北地区新型冠状病毒肺炎的中医特点及防治*[J].西部中医药,2020,33(S1):5.
　DU Honglin,MA Zhanping.TCM Characteristics, the Prevention and Treatment of COVID-19 in Northwest China[J].Western Journal of Traditional Chinese Medicine,2020,33(02):5.
[8]潘文,李盛华,王晓萍,等.中医对新型冠状病毒肺炎的认识与防治探讨[J].西部中医药,2020,33(S1):7.
　PAN Wen,LI Shenghua,WANG Xiaoping,et al.On TCM Understanding, the Prevention and Treatment of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(02):7.
[9]杨海侠,张银萍△,杨长虹,等.新型冠状病毒肺炎疑似患者留观隔离期的护理体会[J].西部中医药,2020,33(S1):13.
[10]丁潇,邹忆怀△,辛大永,等.北京顺义地区新型冠状病毒肺炎的中医临床证候与CT表现[J].西部中医药,2020,33(S1):16.
　DING Xiao,ZOU Yihuai,XIN Dayong,et al.TCM Clinical Syndromes and CT Manifestations of COVID-19 in Shunyi District of Beijing[J].Western Journal of Traditional Chinese Medicine,2020,33(02):16.

备注/Memo

备注/Memo:
王登（1989—），男，硕士学位，主管药师。研究方向：中药药理与临床药学。陕西省自然科学基础研究计划项目（2021JQ-922）。
更新日期/Last Update: 2023-02-15